Global landscape analysis of clinical trials on gut microbiota modulation therapies for irritable bowel syndrome
GMM therapies for IBS are relatively mature. Personalized therapies are necessary; multiomics and emerging therapies (e.g., <i>Akkermansia muciniphila</i>) will promote IBS precision medicine.
Authors
- Junwen Wang (ORCID: https://orcid.org/0000-0002-3301-1190)
- Zining Luo
- Junjie Cao
- Jiebin Xie
- Tianxiang Geng
- Bingbing Li
- Yiting Luo
Institutions
- North Sichuan Medical University (CN)
- Yuhuangding Hospital (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3389/fmed.2026.1737537
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China